查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726286

全球免疫测量市场：市场规模、份额、趋势分析（按产品、应用、最终用途和地区）、细分市场预测（2025-2030 年）

Radioimmunoassay Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Kits), By Application (Research, Clinical Diagnostics), By End Use (Hospitals, Laboratory), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10个工作天内

价格

免疫测量市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球免疫测量市场规模预计到2030年将达到17.9亿美元，2025年至2030年期间的复合年增长率为2.93%。

市场成长背后的驱动力是 RIA 在敏感和特异性诊断应用中的重要角色。儘管新的免疫测量技术不断涌现，RIA 仍然是检测微量荷尔蒙、药物、肿瘤标记和传染性病原体的主要解决方案。主要的市场驱动力是全球慢性病和感染疾病的增加。根据联合国爱滋病规划署估计，到 2023 年，全球爱滋病毒感染者人数将接近 3,990 万人，新增感染人数为 130 万人，反映出对放射免疫分析 (RIA) 等准确可靠的检测方法的持续需求。此外，甲状腺疾病和某些癌症的盛行率不断上升，推动了对精确内分泌和肿瘤诊断的需求。

RIA 技术和试剂的最新进展也促进了市场的成长。 Medipan GmbH 等公司正在延长 TSH、Tg 和抑钙素RIA套件的保质期，从而提高实验室效率。此外，该公司于 2022 年推出的简化 SELco TRAb 一步检测法缩短了甲状腺抗体检测的周转时间并简化了工作流程。策略联盟和收购进一步凸显了市场整合和创新。例如，DiaSorin 对 Luminex Corporation 的收购扩大了其多重测试能力并加强了其在包括 RIA 在内的专业诊断领域的地位。此外，DIAsource 与 Svar Life Science（前身为 Euro Diagnostica）达成的里程碑协议将支持先进免疫检测解决方案的开发，进一步支持 RIA 技术的广泛应用。

免疫测量市场也受到其与临床诊断和研究的相关性的影响。在临床环境中，尤其是医院和诊断实验室，RIA 常规用于荷尔蒙测量和过敏测试，因此占据了相当大的市场占有率。然而，利用 RIA 的高特异性进行生物医学研究的实验室正在推动最快的成长。 LabLogic 系统和自动伽马计数器等先进分析仪器的引入支持了 RIA 工作流程的现代化，并扩大了对高通量应用程式的存取。

实验室晶片(LOC) 技术的进步彻底改变了传统的免疫测量(RIA)。微流体免疫分析平台（μ-RIA）的开发已显着缩短分析时间至约 5 分钟，并最大限度地减少了试剂消费量。这些改进解决了 RIA 先前的局限性，例如较长的​​孵育时间和放射性废弃物的产生，并增强了该技术在临床诊断中的适用性。这些发展凸显了为改善放射性标记和免疫测量方法以及提高诊断影像和标靶诊断的准确性、效率和安全性而做出的共同努力。近日，2025年3月，亚伯达大学的研究人员宣布了一项新的分子影像测试，将单株抗体Panitumumab与放射性同位素铜-64结合。Panitumumab针对的是表皮生长因子受体（EGFR），该受体在非小细胞肺癌细胞中通常过度表现。当用铜-64标记时，这种结合物可以实现精确的 PET 成像，从而有助于早期发现和监测肺癌。这种混合方法为传统切片检查提供了一种非侵入性的替代方法，并可以透过​​及时干预来改善患者的预后。

免疫测量市场：概述

  • 按产品划分，试剂和套件将在 2024 年收益占有率。内分泌、肿瘤学、感染疾病和自体免疫疾病检测对可靠诊断工具的需求不断增长，推动了实验室和医院对 RIA 试剂和试剂套件的消费量大幅增加。这些套件通常含有放射性标记的抗原或抗体（通常用碘-125）、缓衝液、标准品和分离试剂。由于其高灵敏度和特异性，这些套件对于临床实验室检测 TSH、胰岛素、皮质醇、睪固酮和雌二醇等荷尔蒙至关重要。例如，PerkinElmer 和 DIAsource ImmunoAssays 提供多种用于甲状腺功能测试（例如 TSH 和抑钙素）、不孕激素和肿瘤标记的 RIA套件，以支持常规筛检和专门诊断。另一方面，分析仪器预计将成为预测期内成长最快的领域。
  • 从 2024 年免疫测量产业应用来看，由于 RIA 技术在常规和专门的医学检测中的广泛应用，临床诊断将以 76.33% 的以收益为准份额领先于该行业。这项优势主要归功于该技术在检测微量生物标记浓度方面具有出色的灵敏度和特异性，对于准确诊断、疾病监测和治疗计划具有重要意义。预计该研究领域在预测期内将成长最快。
  • 由于医院拥有全面的诊断能力，且需要准确检测生物标记的疾病日益流行，医院在 2024 年占据终端市场主导地位，收入份额达 32.54%。 RIA 具有出色的灵敏度和特异性，因此在医院环境中，它对于准确测量患者样本中的低浓度荷尔蒙、药物和其他物质至关重要。此外，医院采用自动化和先进的 RIA 系统简化了工作流程、缩短了周转时间并提高了结果的准确性。
  • 全球免疫测量市场以北美为主，2024 年的收入份额为 47.43%。成长动力包括先进的医疗保健基础设施、积极的研发 (R&D) 活动以及需要精确诊断工具的慢性病的高盛行率。此外，支持性政策和报销框架正在促进 RIA 在临床诊断中的采用和整合。

目录

第一章 分析方法与范围

第二章执行摘要

第三章放射免疫测量市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
    • 市场机会分析
    • 供应链分析
    • 分销管道
  • 免疫测量市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
  • 医疗费用报销概述
  • 定价分析

第四章免疫测量市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 免疫测量市场：变异分析（按产品划分）（2024 年和 2030 年）
  • 分析器
  • 试剂和套件

第五章免疫测量市场：按应用的估计和趋势分析

  • 细分仪表板
  • 免疫测量市场：变异分析，依应用（2024 年和 2030 年）
  • 研究
  • 临床诊断

第六章免疫测量市场：依最终用途的估计和趋势分析

  • 细分仪表板
  • 免疫测量市场：变异分析，依最终用途划分（2024 年和 2030 年）
  • 医院
  • 临床诊断实验室
  • 製药业
  • 其他的

第七章：免疫测量市场：区域估计与趋势分析

  • 免疫测量市场占有率（按地区划分）（2024 年和 2030 年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 丹麦
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 全球公司市场占有率分析（2024年）
  • 公司热图分析
  • 战略地图
    • 扩张
    • 企业合併与收购（M&A）
    • 伙伴关係和合作
    • 新产品发布
    • 研究与开发
  • 公司简介
    • DIAsource
    • Tecan Trading AG
    • PerkinElmer
    • DRG International Inc.
    • Oxford BioSystems
    • DiaSorin SpA
    • Eurodiagnostico, SL
    • MP Biomedicals
    • Merck KGaA
Product Code: GVR-4-68040-554-8

Radioimmunoassay Market Growth & Trends:

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

  • The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
  • The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
  • The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
  • North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
  • 1.7. Details of primary research
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
      • 1.9.1.1. Approach 1: Commodity flow approach
    • 1.9.2. Volume price analysis (Model 2)
      • 1.9.2.1. Approach 2: Volume price analysis
  • 1.10. Research Scope and Assumptions
    • 1.10.1. List of Secondary Sources
    • 1.10.2. List of Primary Sources
    • 1.10.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
      • 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
      • 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
      • 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Presence of Ambiguous Regulatory Framework
      • 3.2.2.2. High Cost of RIA Equipment
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Supply Chain Analysis
    • 3.2.5. Distribution Channel
      • 3.2.5.1. Direct Sales
      • 3.2.5.2. Distributors Network
      • 3.2.5.3. E-commerce and Online Platforms
      • 3.2.5.4. Major Distributors
  • 3.3. Radioimmunoassay Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Legal landscape
  • 3.4. Reimbursement Overview
  • 3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Analyzers
    • 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Reagents and Kits
    • 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Research
    • 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Clinical Diagnostics
    • 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinical Diagnostics Laboratories
    • 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Pharmaceutical Industries
    • 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

  • 7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.2.3. Competitive Insights
      • 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.3.3. Competitive Insights
      • 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.2.4.3. Competitive Insights
      • 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.2.3. Competitive Insights
      • 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.3.3. Competitive Insights
      • 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.4.3. Competitive Insights
      • 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.5.3. Competitive Insights
      • 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.6.3. Competitive Insights
      • 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.7.3. Competitive Insights
      • 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Denmark
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.8.3. Competitive Insights
      • 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 7.3.9.3. Competitive Insights
      • 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.5.3. Competitive Insights
      • 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.6.3. Competitive Insights
      • 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 7.4.7.3. Competitive Insights
      • 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Global Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research And Development
  • 8.6. Company Profiles
    • 8.6.1. DIAsource
      • 8.6.1.1. Participant's Overview
      • 8.6.1.2. Financial Performance
      • 8.6.1.3. Product Benchmarking
      • 8.6.1.4. Recent Developments
    • 8.6.2. Tecan Trading AG
      • 8.6.2.1. Participant's Overview
      • 8.6.2.2. Financial Performance
      • 8.6.2.3. Product Benchmarking
      • 8.6.2.4. Recent Developments
    • 8.6.3. PerkinElmer
      • 8.6.3.1. Participant's Overview
      • 8.6.3.2. Financial Performance
      • 8.6.3.3. Product Benchmarking
      • 8.6.3.4. Recent Developments
    • 8.6.4. DRG International Inc.
      • 8.6.4.1. Participant's Overview
      • 8.6.4.2. Financial Performance
      • 8.6.4.3. Product Benchmarking
      • 8.6.4.4. Recent Developments
    • 8.6.5. Oxford BioSystems
      • 8.6.5.1. Participant's Overview
      • 8.6.5.2. Financial Performance
      • 8.6.5.3. Product Benchmarking
      • 8.6.5.4. Recent Developments
    • 8.6.6. DiaSorin S.p.A.
      • 8.6.6.1. Participant's Overview
      • 8.6.6.2. Financial Performance
      • 8.6.6.3. Product Benchmarking
      • 8.6.6.4. Recent Developments
    • 8.6.7. Eurodiagnostico, S.L.
      • 8.6.7.1. Participant's Overview
      • 8.6.7.2. Financial Performance
      • 8.6.7.3. Product Benchmarking
      • 8.6.7.4. Recent Developments
    • 8.6.8. MP Biomedicals
      • 8.6.8.1. Participant's Overview
      • 8.6.8.2. Financial Performance
      • 8.6.8.3. Product Benchmarking
      • 8.6.8.4. Recent Developments
    • 8.6.9. Merck KGaA
      • 8.6.9.1. Participant's Overview
      • 8.6.9.2. Financial Performance
      • 8.6.9.3. Product Benchmarking
      • 8.6.9.4. Recent Developments

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Mexico radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 13 Mexico radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 14 Mexico radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 18 Europe radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Germany radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 20 Germany radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 24 UK radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 25 France radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 26 France radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 27 France radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Italy radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 29 Italy radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 30 Italy radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Spain radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 32 Spain radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 33 Spain radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Denmark radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 35 Denmark radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 36 Denmark radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Sweden radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 38 Sweden radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 39 Sweden radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Norway radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 41 Norway radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 42 Norway radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 48 China radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 49 China radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Japan radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 51 Japan radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 52 Japan radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 53 India radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 54 India radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 55 India radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 57 South Korea radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 58 South Korea radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Australia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 60 Australia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 61 Australia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Thailand radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 63 Thailand radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 64 Thailand radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 70 Brazil radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 72 Argentina radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA radioimmunoassay market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait radioimmunoassay market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait radioimmunoassay market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait radioimmunoassay market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Radioimmunoassay market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Parent market outlook, 2024
  • Fig. 10 Radioimmunoassay market driver impact
  • Fig. 11 Radioimmunoassay market restraint impact
  • Fig. 12 Market entry strategy
  • Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Radioimmunoassay market: Product outlook and key takeaways
  • Fig. 16 Radioimmunoassay market: Products movement analysis
  • Fig. 17 Analyzers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Reagents and kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Radioimmunoassay market: Application outlook and key takeaways
  • Fig. 20 Radioimmunoassay market: Application movement analysis
  • Fig. 21 Research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Radioimmunoassay market: End use outlook and key takeaways
  • Fig. 24 Radioimmunoassay market: End use movement analysis
  • Fig. 25 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical diagnostics laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Pharmaceutical industries market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Radioimmunoassay Market: Regional outlook and key takeaways
  • Fig. 30 Radioimmunoassay market: Regional movement analysis
  • Fig. 31 North America
  • Fig. 32 North America. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. key country dynamics
  • Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Canada key country dynamics
  • Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico key country dynamics
  • Fig. 38 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Europe
  • Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 UK key country dynamics
  • Fig. 42 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Germany key country dynamics
  • Fig. 44 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Spain key country dynamics
  • Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Italy key country dynamics
  • Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark key country dynamics
  • Fig. 52 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden key country dynamics
  • Fig. 54 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Norway key country dynamics
  • Fig. 56 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific
  • Fig. 58 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea key country dynamics
  • Fig. 66 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America
  • Fig. 72 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil key country dynamics
  • Fig. 74 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina key country dynamics
  • Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 MEA
  • Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 UAE key country dynamics
  • Fig. 82 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)